---
title: "GUANGXI LIUYAO GROUP released its 2024 annual performance, with a net profit attributable to the parent company of 855 million yuan, a year-on-year increase of 0.62%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233249737.md"
description: "GUANGXI LIUYAO GROUP released its 2024 annual report, with operating revenue of 21.182 billion yuan, a year-on-year increase of 1.78%; net profit attributable to the parent company was 855 million yuan, a year-on-year increase of 0.62%. The net profit excluding non-recurring gains and losses was 837 million yuan, a year-on-year decrease of 0.01%. Basic earnings per share were 2.21 yuan, and it is proposed to distribute a cash dividend of 7.51 yuan for every 10 shares. The company continues to promote product research and development and market expansion in the pharmaceutical industry sector, maintaining steady growth"
datetime: "2025-03-26T08:50:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233249737.md)
  - [en](https://longbridge.com/en/news/233249737.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233249737.md)
---

# GUANGXI LIUYAO GROUP released its 2024 annual performance, with a net profit attributable to the parent company of 855 million yuan, a year-on-year increase of 0.62%

According to the Zhitong Finance APP, Guangxi Liuyao Group (603368.SH) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 21.182 billion yuan, a year-on-year increase of 1.78%. The net profit attributable to shareholders of the listed company was 855 million yuan, a year-on-year increase of 0.62%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 837 million yuan, a year-on-year decrease of 0.01%. The basic earnings per share were 2.21 yuan. It is proposed to distribute a cash dividend of 7.51 yuan (including tax) for every 10 shares to all shareholders.

During the reporting period, the company adhered to the main line of "exploration and innovation" in the pharmaceutical industry sector, continuously promoting product research and development, quality control upgrades, and capacity enhancement. By leveraging commercial channel advantages and forming a professional marketing team, the company has steadily expanded its national market while consolidating its regional market, driving continued steady growth in the pharmaceutical industry sector

### Related Stocks

- [603368.CN](https://longbridge.com/en/quote/603368.CN.md)

## Related News & Research

- [BPCL plans ₹25,000 crore capex for FY27, calls fuel price hike respite](https://longbridge.com/en/news/286942050.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [16:51 ETBeverly Hills MD ProRetinol Age Rewind x3 Officially Launches: A New Era of Gentle, Slow-Released Retinol Skincare Backed by Plastic Surgeons](https://longbridge.com/en/news/286966075.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [LG CNS Expands North American AX Business, Supporting Smart Factory Transformation for SMEs](https://longbridge.com/en/news/286971453.md)